Highly competent, knowledgeable, absolutely reliable and dedicated to the projects
Senior Director
PharmaLex recognizes that medical and scientific literature emerges as a critical information source for benefit-risk evaluation of medicinal products. PharmaLex offers a modular, end-to-end approach to literature surveillance for pharmacovigilance and our experts are flexible enough to offer a tailored solution as well accordingly to client’s requirement.
Global (Indexed) & Local (Non-Indexed) literature surveillance becomes an integral aspect in pharmacovigilance as the main objective of the screening is to identify case reports (ICSRs) and/or any substantially new information from studies (epidemiological, clinical, and non-clinical) pertaining to safety and efficacy. Literature search and review is therefore a critical activity that we undertake for the safety profiling of drugs.
Automated Global and Local Literature surveillance (PubMed and non-indexed journals) | Understanding of full text articles and case processing (ICSRs) | Medical assessment and classification of literature references |
Generate information search strategies with high recall and precision | Quality Review on sample of screened abstracts and articles | Archival & retrieval of abstracts for PV processes e.g., Signal Detection and PSUR(s)/PBRER(s) preparation and benefit-risk evaluation (BRE) of Medicinal Products |
Integration of Medical Literature Monitoring (MLM) service
|
Increased PV search efficiency and accuracy via AI enabled <<< Literature Management Tool – SmartVigilit® >>> | Case reports (ICSRs) in CIOMS I or E2B-compatible (R2 & R3) format with automated communications via email notifications |
Duplicate check performed for all case reports against cases provided by MLM (EMA) | Full text articles purchasing | Translation for foreign language articles |
Highly competent, knowledgeable, absolutely reliable and dedicated to the projects
Worked with us and our contractors to help us achieve our tight targets, operate with our systems and procedures and are considered invaluable part of our team
Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.
We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.
Many thanks for your understanding.
The PharmaLex Team
We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for